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ABSTRACT 25 
 26 
Glycopeptide antibiotics containing a hydrophobic substituent display the best activity against 27 
vancomycin-resistant enterococci, and they have been assumed to be poor inducers of the resistance 28 
system. Using a panel of 26 glycopeptide derivatives and the model resistance system in Streptomyces 29 
coelicolor, we confirm this hypothesis at the level of transcription. Identification of the glycopeptide 30 
structural features associated with inducing resistance gene expression has important implications in 31 
the search for more effective antibiotic structures. 32 
 33 
 34 
Glycopeptides are an important class of antibiotics active against Gram-positive pathogens but 35 
vancomycin and teicoplanin are the only two glycopeptide antibiotics currently used in the clinic. They 36 
exhibit important differences in activity which are believed to be related to their structural differences, 37 
but to date only the mode of action and resistance mechanism to vancomycin has been characterized in 38 
detail. The rapid spread of resistance to these two drugs through pathogenic bacterial populations is an 39 
acute public health concern and the discovery of additional natural or semi-synthetic glycopeptides 40 
with more effective antibiotic activity has been targeted (1). A broad spectrum of vancomycin and 41 
teicoplanin derivatives has previously been generated through chemo-enzymatic synthesis, and their 42 
activity toward pathogenic enterococcal strains determined (2-9). Interestingly, derivatives containing a 43 
hydrophobic substituent were in general found to be significantly more active against both 44 
glycopeptide-sensitive and resistant strains. Dong et al. (8) demonstrated that the key functional 45 
difference between vancomycin and teicoplanin is due to the absence or presence of lipidation, and 46 
evidence that this is related to differing abilities for inducing the resistance system has been obtained in 47 
experiments correlating minimum inhibitory concentrations (MICs) with the activity of VanX enzyme 48 
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or the activity of reporter protein in a transcriptional fusion assay (10-13), but a direct effect on 49 
transcription of the resistance genes has not been investigated. The important implication of this 50 
question, that it is possible to produce glycopeptide structures which are invisible to existing inducible 51 
resistance systems but which retain significant antibiotic activity, has now stimulated us to seek a 52 
definitive answer. Using the vancomycin resistance system in the harmless bacterium Streptomyces 53 
coelicolor as a model, we assay a panel of different natural and semi-synthetic glycopeptide antibiotic 54 
structures for their ability to induce transcription of the van gene cluster (14), and the general cell wall 55 
stress response sigma factor sigE (15), and relate this to the antibiotic activity they exhibit. S. 56 
coelicolor does not synthesize any glycopeptide antibiotic, but does possess a cluster of seven genes 57 
(vanRSJKHAX) conferring inducible resistance to vancomycin but not to teicoplanin (similar to the 58 
phenotype shown in VanB-type VRE), and it offers a safe and convenient model system for the study 59 
of VanB-type glycopeptide resistance (Fig. 1A) (16-21). sigE encodes an extracytoplasmic function 60 
(ECF) sigma factor (σE) which is part of a signal transduction system that senses and responds to 61 
general cell wall stress in S. coelicolor. sigE is constitutively expressed at a low basal level in S. 62 
coelicolor but is also generically induced by a wide-variety of agents that stress the cell wall (Fig. 1B) 63 
(15). 64 
For this study, we have classified all the glycopeptide derivatives analyzed into 4 different groups 65 
according to the substituents located at positions 1 and 3, and the presence or absence of a hydrophobic 66 
group (Fig. 2). Group 1 includes vancomycin aglycones that carry either a non-hydrophobic 67 
carbohydrate or no sugar at all. Group 2 compounds all possess aromatic amino acid residues that are 68 
cross-linked into their core peptide backbone as for teicoplanin but are otherwise similar to Group 1. 69 
Group 3 are hydrophobic derivatives of vancomycin possessing either a teicoplanin-type 70 
monosaccharide containing a saturated lipid or a vancomycin-type disaccharide carrying a 71 
chlorobiphenyl residue. Group 4 includes teicoplanin, dalbavancin and related derivatives all 72 
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containing a saturated lipid as a hydrophobic substituent. Table 1 reports the MIC of each compound 73 
against S. coelicolor in liquid culture. Consistent with the previous observations in VRE strains 74 
according to Dong et al. (8), all the glycopeptide derivatives containing a hydrophobic substituent 75 
(Group 3 and 4) are significantly more active against both vancomycin resistant (wild type) and 76 
sensitive (ΔvanRS) S. coelicolor strains (14). Among all the hydrophobic derivatives, teicoplanin 77 
derivatives (Group 4) generally exhibited greater activity than vancomycin derivatives (Group 3). 78 
Interestingly, hydrophobic group 3 vancomycin derivatives with a chlorobiphenyl (CBP) substituent 79 
were shown to be more active than those with a lipid substituent. To determine the correlation between 80 
the MIC of a derivative and its ability to induce the van resistance system, the abundance of vanH 81 
transcripts in RNA isolated from growing liquid cultures of wild type S. coelicolor (M600) treated by 82 
addition of 10 μg/ml of each glycopeptide derivative was monitored using quantitative real time PCR 83 
(qRT-PCR). Samples taken 30, 60 and 90 min after treatment were compared to a preinduction control 84 
taken immediately before addition (T0), as previously as described (21). sigE transcription was 85 
similarly quantified as a reporter for cell wall stress. Consistent with previous results, vanH 86 
transcription increased immediately in response to vancomycin and reached a maximum level after 30-87 
60 min before beginning to decline (Fig. 3). With the exception of chloroeremomycin, group 1 88 
compounds were typically the best inducers of vanH expression, and all, including chloroeremomycin, 89 
also induced a strong peak in sigE transcript abundance after 30 min. The derivatives in Group 2 90 
behaved similarly, although the maximum level of vanH induction was delayed to 60 min, and the level 91 
of expression was generally weaker. Strikingly, the Group 3 and 4 derivatives containing hydrophobic 92 
substituents exhibited the lowest MIC and all failed to induce vanH transcription - except compound 3a 93 
which showed only a very weak induction of vanH expression - but produced a strong transcriptional 94 
response for sigE. The order of the vanH induction level starting with the best inducer group can 95 
therefore be summarized as Group 1 > Group 2 > Group 3 > Group 4, and this result perfectly 96 
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correlates with the observed MIC result. This implies that the strong activity of glycopeptide 97 
derivatives toward vancomycin resistant bacteria is indeed due to their poor ability to induce the 98 
resistance system. The hydrophobic substituent presumably prevents productive interaction with the 99 
VanS sensor kinase, the key component for triggering the expression of van genes, but has no 100 
detrimental effect on antibiotic activity. Assessment of the cell wall stress response by monitoring the 101 
level of sigE transcription allowed the comparison of MIC values with vanH transcription to be set in a 102 
useful context. Interestingly, sigE was significantly induced following exposure to each compound in 103 
Groups 1 to 4, but its transcription was quickly and continuously reduced only in cases where vanH 104 
expression had also been strongly up-regulated (Fig. 3). In contrast, sigE transcription remained high or 105 
continued to increase if the compound acted as a poor or non-inducer for vanH transcription (i.e. 106 
Groups 3 and 4). This result implies that expression of the sigE system alone is insufficient to produce 107 
a recovery from the cell wall stress created by the glycopeptides. Those compounds which failed to 108 
induce transcription of vanH therefore cause continuous cell wall stress and damage which is in turn 109 
reflected in their improved activity against vancomycin resistant strains. A group of damaged 110 
glycopeptide derivatives produced by Edman degradation or reductive hydrolysis and exhibiting a 111 
significantly reduced affinity toward the D-Ala-D-Ala dipeptide terminus of peptidoglycan precursors 112 
were also analyzed (2). Although the damaged derivatives share virtually identical streochemical 113 
structures with their corresponding parent glycopeptides, their biological activities are vastly different 114 
due to modification of the binding pocket for the D-Ala-D-Ala dipeptide (22, 23). Similar results were 115 
obtained in this study where both damaged vancomycin (D-1a) and teicoplanin (D-4a) exhibited no 116 
activity in the MIC tests, and failed to induce transcription of either vanH or sigE. Interestingly 117 
however, the MIC test showed that both damaged versions of CBP-vancomycin (D-3f) and dalbavancin 118 
(D-4d) retain significant antibiotic activity despite the damage to their D-Ala-D-Ala binding pockets 119 
(Table 1 and Fig. 3). In contrast to D-1a and D-4a, both compounds also induced a low but sustained 120 
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increase in sigE transcription over the 90 min period of the study (Fig. 3). This indicates that these two 121 
derivatives possess a second mode of antibiotic action against cell wall biosynthesis in addition to that 122 
mediated by binding to the D-Ala-D-Ala termini of peptidoglycan precursors. 123 
This work clarifies the relationship between glycopeptide structure, antibiotic activity and the ability to 124 
induce the VanB-type van resistance system. By integrating data from MIC studies with reporters for 125 
transcription of the van resistance (vanH) and cell wall stress response (sigE) systems in an S. 126 
coelicolor model, we confirm for the first time that the activity of glycopeptide derivatives previously 127 
identified against resistant pathogenic Enterococcal strains can be attributed to an inability to activate 128 
transcription of the van resistance system. Derivatives with large hydrophobic substituents were shown 129 
to be the most successful at evading detection by the VanB-type resistance mechanism while still 130 
retaining potent antibiotic activity. Significant activity was also identified in two damaged derivatives 131 
whose structures render them incapable of interacting normally with their D-Ala-D-Ala target groups. 132 
Such structure-activity data has the potential to inform the future design and production of novel, more 133 
effective glycopeptide antibiotic structures. 134 
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 215 
FIG 1 A model illustrating organization and regulation of the vancomycin resistance system (A) and 216 
the SigE system (B) in S. coelicolor. 217 
 218 
FIG 2 Chemical structure of glycopeptide derivatives used in this study. 219 
 220 
FIG 3 Induction of vanH and sigE transcription in S. coelicolor M600 in response to glycopeptide 221 
derivatives. Total RNAs were extracted from each sample and analyzed using qRT-PCR. The X-axis 222 
indicates time (min) after addition of the treatment, and the Y-axis shows the fold change in expression 223 
relative to the level at time 0. Raw qRT-PCR data are presented in Table S1 and S2. For the detailed 224 
experimental procedure, see the experimental section in the supplemental material. 225 
 226 
 227 
 228 
 229 
 230 
 231 
 232 
 233 
 234 
 235 
 236 
 237 
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TABLE 1 MIC (µg/ml) of glycopeptide derivatives against S. coeliicolor in liquid culture. For 238 
experimental details, see the experimental section in the supplemental material. 239 
 
compounds 
Streptomyces coelicolor 
Sensitive (ΔvanRS) Resistant (wild type) 
  
Group 1 
1a  vancomycin 
1b  vancomycin pseudoaglycone 
1c  vancomycin aglycone 
1d  epi-vancomycin 
1e  vancomycin + putrescine 
1f  chloroeremomycin 
1g  balhimycin 
  
  
  0.2 
  0.4 
<0.3 
  0.2 
<0.1 
<0.1 
  0.1 
  
  
>100 
>100 
>100 
>100 
  15 
  20 
  45 
  
  
Group 2 
2a  glucosylated teicoplanin aglycone 
2b  teicoplanin aglycone 
2c  teicoplanin pseudoaglycone 
2d  epi-vanco-Glc teicoplanin 
  
  
  
<0.1 
<0.3 
<0.1 
<0.1 
  
  
  
  20 
  20 
  20 
  10 
  
  
Group 3 
3a  2-aminodecanoyl-Glc vancomycin 
3b  6-aminodecanoyl-Glc vancomycin 
3c  6-aminodecyl-Glc vancomycin 
3d  C6-CBP vancomycin 
3e  C6-amino CBP vancomycin 
3f  CBP vancomycin 
3g  CBP vancomycin + putrescine 
  
  
  0.3 
  0.4 
<0.1 
<0.1 
<0.1 
<0.1 
<0.1 
  
  
  10 
  5 
  1 
  0.2 
<0.1 
<0.1 
0.2 
 
  
Group 4 
4a  teicoplanin 
4b  2-aminodecanoyl-Glc teicoplanin 
4c  6-aminodecanoyl-Glc teicoplanin 
4d  dalbavancin 
  
  
<0.1 
<0.1 
<0.1 
<0.1 
  
  
  0.2 
  3 
  0.2 
<0.1 
 
  
Damaged glycopeptide derivatives 
D-1a  damaged vancomycin 
D-4a  damaged teicoplanin 
D-3f  damaged CBP-vancomycin 
D-4d  damaged dalbavancin 
  
  
>100 
>100 
  2 
  2 
  
  
>100 
>100 
  10 
18 
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FIG 2 Chemical structure of glycopeptide derivatives used in this study.
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FIG 3 Induction of vanH and sigE transcription in S. coelicolor M600 in response to glycopeptide
derivatives. Total RNAs were extracted from each sample and analyzed using qRT-PCR. The X-
axis indicates time (min) after addition of the treatment, and the Y-axis shows the fold change in
expression relative to the level at time 0. Raw qRT-PCR data are presented in Table S1 and S2. For
detailed the experimental procedure, see the experimental section in the supplemental material.
